Record 2025 Revenue Expected to Outpace Guidance—Recorlev, Gvoke, and Keveyis Fuel Momentum
Xeris Biopharma Holdings (NASDAQ:XERS) unveiled its preliminary financial results, forecasting record-breaking total revenue of $292 million for 2025. This estimate stands above the previously guided range of $285 million to $290 million and reflects a remarkable 44% year-over-year increase. These gains underscore commercial execution and enthusiasm across the company’s product portfolio, headlined by Recorlev®, Gvoke®, and Keveyis®.
Recorlev®'s Exceptional Uptake Anchors Growth Prospects
Recorlev®, approved for endogenous Cushing’s syndrome, posted strong momentum in 2025, finishing the year with approximately 700 patients on therapy and net revenue projections of $139 million. This marks a new milestone for the product and highlights robust market adoption following well-executed commercial expansion efforts.
Gvoke® and Keveyis® Deliver Consistent Double-Digit Growth
Gvoke®, Xeris’s ready-to-use glucagon for severe hypoglycemia, saw revenue rise by more than 13% compared to the prior year. Meanwhile, Keveyis®, a therapy for primary periodic paralysis, ended the year with a larger patient base and a notable increase in patients on therapy versus 2024—a clear sign of continued market traction and demand for the treatment suite.
| Product | 2025 Net Revenue ($M) | Growth (%) | Patients on Therapy |
|---|---|---|---|
| Recorlev® | 139 | N/A | 700 |
| Gvoke® | Not Disclosed | 13+ | Not Disclosed |
| Keveyis® | Not Disclosed | Patient Base Grew | Not Disclosed |
Financial Stability and Strategy Set Stage for 2026
One of Xeris’s standout operational achievements has been delivering positive adjusted EBITDA in every quarter of the year. The company also bolstered its intellectual property portfolio: a new Orange Book-listed U.S. patent for Recorlev® and a composition of matter patent for its pipeline candidate XP-8121 ensure longer-term market protection for both commercial and developmental assets.
Looking ahead, CEO John Shannon expressed confidence in Xeris's roadmap: "We enter the year with strong commercial momentum, supported by a robust balance sheet and a clear, disciplined strategy to fuel sustained, long-term, rapid growth across the business." The company also shared its intent to present detailed full-year 2025 financial results and 2026 outlook on March 2, 2026.
Key Takeaways and Upcoming Catalysts
- Total Revenue for 2025 projected at $292 million, outpacing guidance and suggesting accelerated growth trajectory.
- Product Adoption continues to rise, with Recorlev® crossing 700 patients and Gvoke® delivering double-digit revenue growth.
- Profitability Milestone: Positive adjusted EBITDA in every 2025 quarter signals operational discipline and improving margins.
- Intellectual Property Expansion further fortifies the company’s commercial moat and long-term value proposition.
Xeris is positioning itself as a formidable growth story within the biopharma sector, combining product innovation with disciplined execution. With the prospect of full 2025 results and a new 2026 outlook on the horizon, investors and industry watchers will be watching closely to see if this momentum can be sustained—and what surprises might be in store as new products advance through Xeris’s pipeline.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI